Standardizing terms definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

B Rup , M Pallardy , D Sikkema , T Albert , M Allez , P Broet , C Carini , P Creeke , J Davidson , N De Vries , D Finco , A Fogdell-Hahn , E Havrdova , A Hincelin-Mery , M C Holland , P E H Jensen , E C Jury , H Kirby , D Kramer , S Lacroix-Desmazes , J Legrand , E Maggi , B Maillère , X Mariette , C Mauri , V Mikol , D Mulleman , J Oldenburg , G Paintaud , C R Pedersen , N Ruperto , R Seitz , S Spindeldreher , F Deisenhammer

(Clin Exp Immunol. 2015 Sep;181(3):385-400 – PMID: 25959571)

https://pubmed.ncbi.nlm.nih.gov/25959571/